Bank of America Corp DE Cuts Holdings in OrthoPediatrics Corp. (NASDAQ:KIDS)

Bank of America Corp DE cut its position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 25.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 79,595 shares of the company's stock after selling 27,572 shares during the quarter. Bank of America Corp DE owned approximately 0.33% of OrthoPediatrics worth $1,845,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wasatch Advisors LP boosted its stake in OrthoPediatrics by 47.2% in the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company's stock valued at $16,141,000 after acquiring an additional 223,217 shares during the last quarter. Wellington Management Group LLP boosted its stake in OrthoPediatrics by 20.2% in the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock valued at $24,601,000 after acquiring an additional 178,078 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in OrthoPediatrics by 29.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock valued at $15,576,000 after acquiring an additional 152,681 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in OrthoPediatrics by 129.8% in the fourth quarter. Kennedy Capital Management LLC now owns 249,978 shares of the company's stock valued at $5,794,000 after acquiring an additional 141,174 shares during the last quarter. Finally, Mutual of America Capital Management LLC boosted its stake in OrthoPediatrics by 57.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company's stock valued at $3,918,000 after acquiring an additional 61,412 shares during the last quarter. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Price Performance

OrthoPediatrics stock traded up $0.33 during midday trading on Friday, reaching $21.19. 241,054 shares of the stock were exchanged, compared to its average volume of 199,453. The company's fifty day moving average is $21.66 and its 200-day moving average is $23.47. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The firm has a market cap of $514.64 million, a PE ratio of -17.23 and a beta of 1.08. OrthoPediatrics Corp. has a 52 week low of $19.52 and a 52 week high of $35.99.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The firm had revenue of $52.41 million for the quarter, compared to the consensus estimate of $51.68 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. On average, sell-side analysts forecast that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Insider Buying and Selling

In related news, insider Gregory A. Odle sold 5,359 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the sale, the insider now owns 148,788 shares of the company's stock, valued at approximately $3,698,869.68. This represents a 3.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the company's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares in the company, valued at $2,753,667.62. This trade represents a 4.57% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,732 shares of company stock valued at $589,978. Company insiders own 32.70% of the company's stock.

Analyst Upgrades and Downgrades

KIDS has been the topic of a number of research analyst reports. Piper Sandler dropped their target price on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen lowered shares of OrthoPediatrics from a "hold" rating to a "sell" rating in a research report on Friday. Needham & Company LLC reissued a "buy" rating and issued a $42.00 price target on shares of OrthoPediatrics in a research report on Thursday, May 8th. Lake Street Capital started coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 price target on the stock. Finally, Stifel Nicolaus lowered their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, OrthoPediatrics currently has an average rating of "Moderate Buy" and a consensus target price of $35.83.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.